Navigation Links
Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Date:6/28/2010

to clinically meaningful outcomes for patients.  It is compelling that these data showed a strong correlation between blood glucose variability and C-peptide, particularly because glucose variability was measured with basic finger stick blood glucose testing. Tolerx is seeking additional and more robust data from the ongoing confirmatory Phase 3 DEFEND-2 study in which all subjects will wear a continuous glucose monitor (CGM) at regular intervals," said Aoife Brennan, MD, endocrinologist and Associate Medical Director at Tolerx.  "Our Phase 3 DEFEND-1 and DEFEND-2 clinical trials aim to show that otelixizumab is not only safe and well tolerated, but that it preserves beta cell function."

The Tolerx data presentation at ADA (abstract #700-P), entitled "Lower C-Peptide Secretion Is Associated With Increased Blood Glucose Variability In Adults With New-Onset Type 1 Diabetes: Analysis Of Baseline Data From DEFEND-1," reviewed data from patients within 90 days of diagnosis with new-onset diabetes, monitoring their blood glucose 7 times per day for 7 days prior to the date when the patients began dosing with Tolerx's investigational product candidate, otelixizumab. Two measurements of glucose variability were evaluated for relationship to C-peptide: average daily risk range (ADRR) and mean amplitude of glycemic excursions (MAGE).   With a decrease in each measure of glucose variability, ADRR and MAGE, there was a statistically significant correlation with an increase in C-peptide.  The results demonstrate the relationship between glucose variability and C-peptide, confirming that C-peptide is a robust and important clinical marker for beta cell function and glycemic control.

About the DEFEND-1 Study

DEFEND-1 is a randomized, placebo-controlled Phase 3 study that has achieved its target enrollment of 240 patients, age 12
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
2. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
3. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
4. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
5. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
9. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
10. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
11. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... BCR-ABL That Cause Resistance to Current ... CML and ALL ... ) today reported preliminary phase 1 data from an ongoing,trial of ... lymphocytic leukemia (Ph+ALL) who,are resistant to or intolerant of the approved ...
... Also Experienced Improved Physical Functioning, INDIANAPOLIS, June ... pain of the knee treated with 60 mg ... significant pain,reduction. Patients taking duloxetine reported significant pain ... treatment that lasted,throughout the 13-week trial.(1) Results from ...
Cached Medicine Technology:Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 2Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 3Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 3Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 5
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body ... boot camp has held two charity workout events and is ... 26th, from 7:15 - 8:30 at Col Summers City Park, SE ... camp session raised $510 for Medical Teams International. Their second workout ... a Dream. On July 26th, Johnson and Portland Fit Body ...
(Date:7/11/2014)... 2014 As reported by Forbes in ... Are Genetics To Blame (6/30), Indino Downey has reportedly ... paraphernalia to smoke it with. His father, well-known actor ... son inherited from him may have something to do ... news during the 1980s and 1990s for substance abuse ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 ... today announces that he uses mini and full mouth ... offer the defining feature that distinguishes dental implants from ... in addition to the crowns. This alone prevents the ... also offer advantages related to comfort, appearance and ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... For breast cancer patients, the era of personalized medicine ... advances by USC Stem Cell researcher Min Yu and ... , In a July 11 study in Science ... breast cancer cells circulating through the blood streams of ... the "seeds" of metastasis, which travel to and establish ...
Breaking Medicine News(10 mins):Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2
... by the Canadian Association for Adolescent Health has found that ... are ignorant about important sex information.// ,The survey ... in casual sex and a half-million sexually active teens aged ... of teens claimed to have some knowledge about sex, but ...
... The infant formula Gentlease is being recalled from the market ... of metal particles in some cans. // So this brand ... makers of Gentlease powdered infant formula, Mead Johnson Nutritionals of ... batch number BMJ19 printed on the bottom of the cans. ...
... that swimming helps immensely the children to stay hale ... ,Researches conducted over six years at the Jigalong, ... examined the impact on children's health where swimming pools ... Institute for Child Health Research study found that at ...
... can do more than affecting just your gums. It ... premature delivery. // The following is the conclusion arrived ... York. ,Participants at the conference highlighted the ... association with gum disease. They further reflected the need ...
... level of which is strongly suggestive of prostate cancer in ... early signs of prostate cancer, // if any. A new ... needed for establishment of prostate cancer diagnosis in young men ... researchers from Duke University Medical Center analyzed more than 12,000 ...
... who is the principle investigator said that the new technique ... to discover molecules that can enhance or block different kinds ... succeeded in growing mature taste receptor cells outside the body. ... for a prolonged period of time. This is a break ...
Cached Medicine News:Health News:Unhealthy Gums Increase Risk Of Premature Delivery 2Health News:Functional Taste Cells Cultured In Vitro 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: